Fig. 2

Flow Chart from the Pilot Testing. A total of 1350 low value technologies were reviewed from the three source lists. Twelve-hundred and seventy-six were excluded because the language in the recommendation was clinically nuanced (n = 552), it referred to drug technologies (n = 474), technologies were not publicly-funded in the BC health system (n = 178), had no identifiable service/procedural, billing or fee item code (n = 60), or were duplicates (n = 12). Seventy-four low value technologies were coded and, of these, 47 were found to have frequencies and costs between April 1, 2010 and March 31, 2015. Nine potential candidate technologies were prioritized based on high budgetary impact (costs > $1 M in a fiscal year). The expert advisory committee, particularly the clinical stakeholders, reviewed the technologies with identified frequencies and costs and provided feedback on the prioritized candidate technologies to ensure relevancy and feasibility for HTR